A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
About the study
The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
Pterygium with conjunctival hyperemia
EXCLUSION CRITERIA
Exclusion Criteria:
Pterygium removal within the last 6 months
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Pterygium
Age
12+
Phase
PHASE3
Participants Needed
600
Est. Completion Date
Dec 31, 2026
Treatment Type
INTERVENTIONAL
Sponsor
Cloudbreak Therapeutics, LLC
ClinicalTrials.gov NCT Identifier
NCT05456425
Study Number
CBT-CS301
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?